<DOC>
	<DOCNO>NCT02529553</DOCNO>
	<brief_summary>The main purpose study evaluate safety study drug know LY3076226 participant advance metastatic cancer .</brief_summary>
	<brief_title>A Study LY3076226 Participants With Advanced Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>Have advance metastatic cancer appropriate candidate experimental therapy . Part B : Have diagnosis bladder cancer . Part B C : Have alteration FGFR3 . Have adequate organ function . Have discontinue previous treatment cancer resolution , except otherwise state inclusion criterion , clinically significant toxic effect prior chemotherapy , surgery , radiotherapy Grade ≤1 National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , Version 4.0 ( v 4.0 ) . If participant reproductive potential , must agree use medically approve contraceptive precaution study 3 month follow last dose study drug . If participant female childbearing potential , must negative serum urine pregnancy test within 7 day first dose study drug must breastfeed . Have receive treatment within 28 day initial dose study drug investigational product nonapproved use drug device ( study drug/device use study ) concurrently enrol type medical research judge scientifically medically compatible study . Have preexist corneal disease may interfere assessment potential eye toxicity study . Have preexist Grade ≥2 skin disorder ( example , erythema , dermatitis ) . Have serious preexist medical condition ( leave discretion investigator ) . Have symptomatic central nervous system ( CNS ) malignancy metastasis ( screen require ) . Participants treat CNS metastasis eligible study currently receive corticosteroid and/or anticonvulsant , disease asymptomatic radiographically stable least 28 day . Have current acute chronic leukemia . Have active fungal , bacterial , and/or know viral infection include human immunodeficiency virus ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) . Have second primary malignancy , judgment investigator sponsor , may affect interpretation result . Curatively treated nonmelanoma skin cancer situ carcinoma origin allow . Have Fridericiacorrected QT interval ( QTcF ) &gt; 480 millisecond screen electrocardiogram ( ECG ) . Have serious cardiac condition , congestive heart failure ; New York Heart Association Class III/IV heart disease ; unstable angina pectoris ; myocardial infarction within last 3 month ; valvulopathy severe , moderate , deem clinically significant ; arrhythmias symptomatic require treatment ( include participant ratecontrolled atrial fibrillation ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>bladder cancer</keyword>
</DOC>